NAFDAC Reg No. A7-0694L Made in the USA Manufacturer: AMERICAN JBD

Slides:



Advertisements
Similar presentations
LACTOFERRIN The Foundation of Life Reinforces the natural defenses of the body.
Advertisements

Spirulina Immune System Booster. Spirulina Spirulina or Arthrospira platensis is a uni-cellular microalgae which grows in fresh water, in salt water,
Ethnobotanical study of nutri-medicinal plants used in the management of HIV/AIDS opportunistic ailments in western Uganda : A Case Study of Isingiro district.
The innovative Swiss pharmaceutical company Mesporin: Mepha Health Care.. for Post-operative Infection.
{ Chapter 47 The Immune system.  What is a pathogen?  Any agent that causes disease  Koch was the first to establish how to identify individual pathogens.
Echinacea Not the Miracle Drug for Tomorrow Teresa Cantwell Issues of Science and Technology Nora Demers.
PROPOLIS and CANCER An Alternative and Supplemental Therapy CMAC 2009 Glenn Perry.
Cancer vaccines are biological response modifiers. They prime the immune system to attack the cancer cells in the body. The goal is to prevent or to treat.
Introducing Apceden™.
HIV/AIDS Treating the Symptoms with Vitamins and Herbs MDyer_HW499-01_Unit 4 Assignment.
Treatment of HIV/AIDS Lindsay Henry. Prevention methods for HIV/AIDS? Are barrier methods 100% effective? What is the most effective barrier method? How.
Healthy Trac™ Market For Digestive Health #2 Retail Product Category ($2 Billion). 60 Million Suffer Digestive Health Problems Each Year. #1 Reason For.
Biology and natural history of the virus
Chapter 40 “The Immune System”
Herbal Medicine. Herbal medicine has been used for thousands of years. Healing rituals Ayurveda Traditional Chinese Medicine (TCM)
1 Body Defenses, Immunity & Vaccines Chapter The Immune System Protects us from harmful agents and is made up if blood cells and the lymphatic system.
Biomedical Technology Unit Treatment for heart disease Heart-lung machine Treatment for cancer Treatment for diabetes Bone marrow transplants.
Diseases Learning Targets and Success Criteria. Infection Learning Target I can explain how viruses, bacteria, fungi and parasites may infect the human.
Approved: 9 Jun DoD Leader’s Briefing: Force Health Protection Against Anthrax.
KEY CONCEPT Some viral diseases can be prevented with vaccines.
OLISFERROL® [C 119 H 163 Fe 2 N S 4 ] 500-mcg Capsule; 5-mg I.V. Made in the USA Manufacturer: BAC Pharmaceuticals, USA, 7362 Remcon Circle Suite.
By ALB Digestive Physiology
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 7 Over-the-Counter Drugs and Herbal and Dietary.
Vitrasert Ganciclovir Intraocular Implant Reservoir style implant used for the delivery of the anti-viral prodrug ganciclovir. Vitrasert was the first.
The Immune System: Video Response Notes Part 1 Part 1 1.Which part of the body must the influenza-B virus reach in order to survive and multiply? 2.How.
Immune System SC.912.L Explain the basic functions of the human immune system, including specific and nonspecific immune response, vaccines, and.
Other Modes of Treatment
Pharmaceutical Composition Claims and Enablement Robert J. Hill, Jr. Quality Assurance Specialist Technology Center
IMMUNOTHERAPY. is a medical term defined as "treatment of disease by inducing, enhancing, or suppressing an immune response.
Genetic DNA Vaccines By Chelsea Heimbrock. What are DNA Vaccines? An injection of genes of a virus into the body that creates an immune response for the.
Hepatitis web study Hepatitis web study Simeprevir versus Telaprevir with PR in GT1 ATTAIN Trial Phase 3 Treatment Experienced Reddy KR, et al. Lancet.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in HCV Genotype 4 NIAID SYNERGY (Genotype 4) Phase 2 Treatment Naïve and Treatment Experienced.
ENCOURAGES IMMUNITY CONSUMING NUTRIENTS. Content Introduction LIST OF SUPERIOR IMMUNITY BOOSTERS Zinc Carotenoids Herbs Garlic Astragalus Selenium Echinacea.
Infectious Disease & The Immune System. Disease Disease – any change, other than injury, that disrupts the normal functions of the body Some diseases.
Immune System Review. Prevention Diagnosis Treatment Cure.
Focus On Nonvitamin/ Nonmineral Supplements. Copyright 2010, John Wiley & Sons, Inc. Types of Dietary Supplements.
Dose and range (mg/kg body weight)
NUTRACEUTICAL FORMULATION TECHNOLOGY HHV 5014
Data from Bouri et al.1 Source: Understanding and Applying the Results of a Systematic Review and Meta-analysis, Users' Guides to the Medical Literature:
Over-the-Counter Drugs and Herbal and Dietary Supplements
KEY CONCEPT Some viral diseases can be prevented with vaccines.
Progression After Cancer Immunotherapy in Advanced NSCLC
Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.
Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.
Advances in Immunotherapy for Peanut Allergy
Immune System.
Yong-jiang Hei  European Urology Supplements 
Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.
In vivo efficacy of gemcitabine and MK-1775.
Preventing Medication Errors (p. 71)
Public health measures toward prevention
Antitumor effects of FF and gemcitabine on two pancreatic PDX models.
Prioritizing Prevention of HPV-Related Disease
Reducing antibiotic use in influenza: challenges and rewards
KEY CONCEPT Some viral diseases can be prevented with vaccines.
Activity of MAC-321 (i. v. and p. o
Effect of MI-773 dosing on long-term efficacy.
Fig. 1. Iontophoretic devices used for the delivery of cytotoxic agents to solid tumors. Iontophoretic devices used for the delivery of cytotoxic agents.
KEY CONCEPT The immune systems consists of organs, cells, and molecules that fight infections. Benchmark SC.912.L.14.52: Explain the basic functions of.
KEY CONCEPT Some viral diseases can be prevented with vaccines.
KEY CONCEPT Some viral diseases can be prevented with vaccines.
Positive correlations between disease course and treatment-induced immune responses. Positive correlations between disease course and treatment-induced.
Antitumor effects of celastrol in vitro and in vivo.
DAC treatment alters immune cell composition and enhances cytokine production in the peritoneal lavage. DAC treatment alters immune cell composition and.
Pros and cons for neoadjuvant immunotherapy.
MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.
Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.
Proliferation of TA3-Ha and TA3-St cells in vitro and in vivo.
Curative effect of W+T treatment in vivo.
AMG 176 exhibits robust single-agent activity in vivo.
Presentation transcript:

Olisferrol® [braunmycin] 500-mcg organic-herbal; 5-mg adjuvant-water- I.V. NAFDAC Reg No. A7-0694L WWW.OLISFERROL.COM Made in the USA Manufacturer: AMERICAN JBD 2521 N. Main Street Unit 1 -206 Las Cruces NM 88001 P: +1 (915) 208 4431 E: admin@olisa.org US FDA Drug Est. Reg. No. 2512009 US Patent No. 7,244,702 B7 US Library of Congress Copyright Reg No. TXU 1- 100-385

INTRODUCTION Source: Time magazine September 14, 2009 pp. 32-39

INTRODUCTION Source: Time magazine September 14, 2009 pp. 32-39

INTRODUCTION Source: Time magazine September 14, 2009 pp. 32-39

WHAT IS OLISFERROL ®? Olisferrol® C119H163Fe2N29071S4] is an organic adjuvant therapeutic preparation derived from the Native American herbs: Echinacea and Goldenseal roots Olisferrol® C119H163Fe2N29071S4] activates macrophages and dendritic cells to produce all natural human antibiotics. Like: Interferon-γ, Tumor Necrotic factors (TNFα) Other antibiotics that are similar in class include the following: Lactoferrin Defensins Bacitracin Nisin

The most recent ones include the following references: Echinacea has been used by Native Americans for over 3,000 years as a non specific type of antibiotics. There are over 3,000 published reports in scientific peer journals on efficacy of Echinacea. The most recent ones include the following references: Cancer Vaccines. Time Magazine pp. 32-39 September 14, 2009. The AIDS Vaccine. Time Magazine pp. 65 November 23, 2009. Olisa, N.R. Research and Development of Braunmycin® Olisferrol™. Biological Agents Index 3rd Ed ISBN 978-0-615-18915-5. American Journal of Biological Defense. pp. 96-99, 2008. Sachin et al., Evaluation of Echinacea for the prevention and treatment of the common cold. Meta Analysis. Lancet Infect Dis. pp. 473-480. 2007  Miller, S. Echinacea: Miracle herb against aging and cancer? Evidence in vivo in mice. eCAM,Oxford University press. 2005 2(3)309-314

WHAT IS OLISFERROL ® USED FOR? To enhance natural immunity (Body Booster) to non-specific infections To enhance natural immunity (Body Booster) during immunotherapy against Cancer To enhance natural immunity (Body Booster) AGAINST Opportunistic Infections Associated with HIV/AIDS To enhance natural immunity (Body Booster) AGAINST Cold/Flu-like Infections

HOW IS OLISFERROL ® DOSED ? All natural approach 500-mcg herbal/dietary supplement Prescription approach 5-mg Intravenously via normal saline I.V. (adjuvant water)

HOW DOES OLISFERROL® WORK? Miller, S. Echinacea: Miracle herb against aging and cancer? Evidence in vivo in mice. eCAM,Oxford University press. 2005 2(3)309-314

WHO SHOULD TAKE OLISFERROL®? EVERYONE should take herbal dietary supplement Once daily 2-3 hours before meals Supplement can limit onset of some cancers, and infections. Miller, S et al (2005); Sachin et al, (2007). People with stage IV cancer can receive I.V to limit the aggression of disease. (Cancer Vaccines. Time Magazine pp. 32-39 September 14, 2009) People living with HIV/AIDS can receive I.V to limit opportunistic infections associated with disease

WHAT IS THE EFFICACY OF USING IMMUNOTHERAPY TO MANAGE CANCER? Source: Time magazine September 14, 2009 pp. 32-39